Quizartinib Triplet Shows Activity in Heavily Pretreated, FLT3-ITD–Mutated AML - OncLive
6/11/2022 12:00:00 AM2 years 10 months ago
by Kristi Rosa
by Kristi Rosa
The triplet combination regimen comprised of quizartinib, decitabine, and venetoclax elicited encouraging responses in heavily pretreated patients with relapsed/refractory FLT3-ITD–mutated acute myeloid leukemia who were previously exposed to a FLT3 inhibitor.
The triplet combination regimen comprised of quizartinib, decitabine, and venetoclax (Venclexta) elicited encouraging responses in heavily pretreated patients with relapsed/refractory FLT3-ITDmutated… [+10113 chars]
full article...